title: Atrial fibrillation: overview of therapeutic trials.
abstract: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia treated by physicians, and a plethora of therapeutic trials deal with selected aspects of its management. This overview attempts to categorize and summarize the available studies. A key to management of AF is a clinical classification schema that provides a framework for application of the available treatment modalities. Such a classification is provided. Antithrombotic trials have demonstrated the remarkable efficacy of warfarin and more modest effect of acetylsalicylic acid for prevention of stroke; these data are summarized. Cardioversion to restore sinus rhythm is an important aspect of management of AF, particularly of persistent and new onset AF. In this review pharmacological cardioversion is emphasized. The data concerning the use of various drugs for pharmacological cardioversion are reviewed. Many, but not all, agents have been shown to have efficacy in this regard, but efficacy with drugs is lower than that with electrical cardioversion and, in the case of amiodarone, may be delayed. For recurrent AF, the two major rhythm management approaches are maintenance of rhythm and heart rate control. Trials of pharmacological and nonpharmacological therapies for these purposes are reviewed and summarized. Management of AF is an active area of research, and the present review is intended as a foundation upon which new information can be added.
authors.affiliation: Division of Cardiology, University of Calgary, Alberta.
authors.forename: M N
authors.initials: MN
authors.lastname: Sharif
authors.forename: D G
authors.initials: DG
authors.lastname: Wyse
mesh_terms: D000367:Age Factors; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000145:classification / Q000628:therapy*; D002304:Cardiac Pacing, Artificial; D002986:Clinical Trials as Topic; D004554:Electric Countershock / Q000379:methods; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006339:Heart Rate; D006801:Humans; D008297:Male; D015912:Thrombolytic Therapy; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000889:Anti-Arrhythmia Agents; D005343:Fibrinolytic Agents; D014859:Warfarin; D001241:Aspirin